Loading…

Exploring the Potential of ILactobacillus helveticus/I R0052 and IBifidobacterium longum/I R0175 as Promising Psychobiotics Using SHIME

Psychobiotics are probiotics that have the characteristics of modulating central nervous system (CNS) functions or reconciled actions by the gut–brain axis (GBA) through neural, humoral and metabolic pathways to improve gastrointestinal activity as well as anxiolytic and even antidepressant abilitie...

Full description

Saved in:
Bibliographic Details
Published in:Nutrients 2023-03, Vol.15 (6)
Main Authors: De Oliveira, Fellipe Lopes, Salgaço, Mateus Kawata, de Oliveira, Marina Toscano, Mesa, Victoria, Sartoratto, Adilson, Peregrino, Antonio Medeiros, Ramos, Williams Santos, Sivieri, Katia
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 6
container_start_page
container_title Nutrients
container_volume 15
creator De Oliveira, Fellipe Lopes
Salgaço, Mateus Kawata
de Oliveira, Marina Toscano
Mesa, Victoria
Sartoratto, Adilson
Peregrino, Antonio Medeiros
Ramos, Williams Santos
Sivieri, Katia
description Psychobiotics are probiotics that have the characteristics of modulating central nervous system (CNS) functions or reconciled actions by the gut–brain axis (GBA) through neural, humoral and metabolic pathways to improve gastrointestinal activity as well as anxiolytic and even antidepressant abilities. The aim of this work was to evaluate the effect of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 on the gut microbiota of mildly anxious adults using SHIME[sup.®]. The protocol included a one-week control period and two weeks of treatment with L. helveticus R0052 and B. longum R0175. Ammonia (NH4+), short chain fatty acids (SCFAs), gamma-aminobutyric acid (GABA), cytokines and microbiota composition were determined. Probiotic strains decreased significantly throughout the gastric phase. The highest survival rates were exhibited by L. helveticus R0052 (81.58%; 77.22%) after the gastric and intestinal phase when compared to B. longum (68.80%; 64.64%). At the genus level, a taxonomic assignment performed in the ascending colon in the SHIME[sup.®] model showed that probiotics (7 and 14 days) significantly (p < 0.005) increased the abundance of Lactobacillus and Olsenella and significantly decreased Lachnospira and Escheria-Shigella. The probiotic treatment (7 and 14 days) decreased (p < 0.001) NH[sub.4] [sup.+] production when compared to the control period. For SCFAs, we observed after probiotic treatment (14 days) an increase (p < 0.001) in acetic acid production and total SCFAs when compared to the control period. Probiotic treatment increased (p < 0.001) the secretion of anti-inflammatory (IL-6 and IL-10) and decreased (p < 0.001) pro-inflammatory cytokines (TNF-alpha) when compared to the control period. The gut–brain axis plays an important role in the gut microbiota, producing SCFAs and GABA, stimulating the production of anti-anxiety homeostasis. The signature of the microbiota in anxiety disorders provides a promising direction for the prevention of mental illness and opens a new perspective for using the psychobiotic as a main actor of therapeutic targets.
doi_str_mv 10.3390/nu15061521
format article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A743769164</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743769164</galeid><sourcerecordid>A743769164</sourcerecordid><originalsourceid>FETCH-LOGICAL-g674-dfc3088cb8ba7d78c228653fa28e52edcf7cd91d3ceb40f23997ac32a1d29daf3</originalsourceid><addsrcrecordid>eNptkMtOwzAQRS0EElXphi-wxDqtH4mdLEtVaKQiKijryvEjNXJsFCcIvqC_TVpYdMHMYkZXZ-6MBoBbjKaUFmjme5whhjOCL8CIIE4SxlJ6edZfg0mM7-gYHHFGR-Cw_PpwobW-ht1ew03otO-scDAYWK6F7EIlpHWuj3Cv3afurOzjrIQvCGUECq9geW-NVUes063tG-iCr_vmxGCeQRHhpg2Njccdm_gt96GyYfCJ8O2kva7Kp-UNuDLCRT35q2OwfVhuF6tk_fxYLubrpGY8TZSRFOW5rPJKcMVzSUjOMmoEyXVGtJKGS1VgRaWuUmQILQouJCUCK1IoYegY3P3a1sLpnfUmdK2Qw3FyN-cp5azAw5vGYPoPNaTSjZXBa2MH_WzgB4S3czY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Exploring the Potential of ILactobacillus helveticus/I R0052 and IBifidobacterium longum/I R0175 as Promising Psychobiotics Using SHIME</title><source>Publicly Available Content (ProQuest)</source><source>PubMed</source><creator>De Oliveira, Fellipe Lopes ; Salgaço, Mateus Kawata ; de Oliveira, Marina Toscano ; Mesa, Victoria ; Sartoratto, Adilson ; Peregrino, Antonio Medeiros ; Ramos, Williams Santos ; Sivieri, Katia</creator><creatorcontrib>De Oliveira, Fellipe Lopes ; Salgaço, Mateus Kawata ; de Oliveira, Marina Toscano ; Mesa, Victoria ; Sartoratto, Adilson ; Peregrino, Antonio Medeiros ; Ramos, Williams Santos ; Sivieri, Katia</creatorcontrib><description>Psychobiotics are probiotics that have the characteristics of modulating central nervous system (CNS) functions or reconciled actions by the gut–brain axis (GBA) through neural, humoral and metabolic pathways to improve gastrointestinal activity as well as anxiolytic and even antidepressant abilities. The aim of this work was to evaluate the effect of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 on the gut microbiota of mildly anxious adults using SHIME[sup.®]. The protocol included a one-week control period and two weeks of treatment with L. helveticus R0052 and B. longum R0175. Ammonia (NH4+), short chain fatty acids (SCFAs), gamma-aminobutyric acid (GABA), cytokines and microbiota composition were determined. Probiotic strains decreased significantly throughout the gastric phase. The highest survival rates were exhibited by L. helveticus R0052 (81.58%; 77.22%) after the gastric and intestinal phase when compared to B. longum (68.80%; 64.64%). At the genus level, a taxonomic assignment performed in the ascending colon in the SHIME[sup.®] model showed that probiotics (7 and 14 days) significantly (p &lt; 0.005) increased the abundance of Lactobacillus and Olsenella and significantly decreased Lachnospira and Escheria-Shigella. The probiotic treatment (7 and 14 days) decreased (p &lt; 0.001) NH[sub.4] [sup.+] production when compared to the control period. For SCFAs, we observed after probiotic treatment (14 days) an increase (p &lt; 0.001) in acetic acid production and total SCFAs when compared to the control period. Probiotic treatment increased (p &lt; 0.001) the secretion of anti-inflammatory (IL-6 and IL-10) and decreased (p &lt; 0.001) pro-inflammatory cytokines (TNF-alpha) when compared to the control period. The gut–brain axis plays an important role in the gut microbiota, producing SCFAs and GABA, stimulating the production of anti-anxiety homeostasis. The signature of the microbiota in anxiety disorders provides a promising direction for the prevention of mental illness and opens a new perspective for using the psychobiotic as a main actor of therapeutic targets.</description><identifier>ISSN: 2072-6643</identifier><identifier>EISSN: 2072-6643</identifier><identifier>DOI: 10.3390/nu15061521</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Anxiety ; Bifidobacterium ; Development and progression ; Diet therapy ; Gastrointestinal system ; Health aspects ; Lactobacillus ; Microbiota (Symbiotic organisms) ; Physiological aspects ; Probiotics</subject><ispartof>Nutrients, 2023-03, Vol.15 (6)</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>De Oliveira, Fellipe Lopes</creatorcontrib><creatorcontrib>Salgaço, Mateus Kawata</creatorcontrib><creatorcontrib>de Oliveira, Marina Toscano</creatorcontrib><creatorcontrib>Mesa, Victoria</creatorcontrib><creatorcontrib>Sartoratto, Adilson</creatorcontrib><creatorcontrib>Peregrino, Antonio Medeiros</creatorcontrib><creatorcontrib>Ramos, Williams Santos</creatorcontrib><creatorcontrib>Sivieri, Katia</creatorcontrib><title>Exploring the Potential of ILactobacillus helveticus/I R0052 and IBifidobacterium longum/I R0175 as Promising Psychobiotics Using SHIME</title><title>Nutrients</title><description>Psychobiotics are probiotics that have the characteristics of modulating central nervous system (CNS) functions or reconciled actions by the gut–brain axis (GBA) through neural, humoral and metabolic pathways to improve gastrointestinal activity as well as anxiolytic and even antidepressant abilities. The aim of this work was to evaluate the effect of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 on the gut microbiota of mildly anxious adults using SHIME[sup.®]. The protocol included a one-week control period and two weeks of treatment with L. helveticus R0052 and B. longum R0175. Ammonia (NH4+), short chain fatty acids (SCFAs), gamma-aminobutyric acid (GABA), cytokines and microbiota composition were determined. Probiotic strains decreased significantly throughout the gastric phase. The highest survival rates were exhibited by L. helveticus R0052 (81.58%; 77.22%) after the gastric and intestinal phase when compared to B. longum (68.80%; 64.64%). At the genus level, a taxonomic assignment performed in the ascending colon in the SHIME[sup.®] model showed that probiotics (7 and 14 days) significantly (p &lt; 0.005) increased the abundance of Lactobacillus and Olsenella and significantly decreased Lachnospira and Escheria-Shigella. The probiotic treatment (7 and 14 days) decreased (p &lt; 0.001) NH[sub.4] [sup.+] production when compared to the control period. For SCFAs, we observed after probiotic treatment (14 days) an increase (p &lt; 0.001) in acetic acid production and total SCFAs when compared to the control period. Probiotic treatment increased (p &lt; 0.001) the secretion of anti-inflammatory (IL-6 and IL-10) and decreased (p &lt; 0.001) pro-inflammatory cytokines (TNF-alpha) when compared to the control period. The gut–brain axis plays an important role in the gut microbiota, producing SCFAs and GABA, stimulating the production of anti-anxiety homeostasis. The signature of the microbiota in anxiety disorders provides a promising direction for the prevention of mental illness and opens a new perspective for using the psychobiotic as a main actor of therapeutic targets.</description><subject>Anxiety</subject><subject>Bifidobacterium</subject><subject>Development and progression</subject><subject>Diet therapy</subject><subject>Gastrointestinal system</subject><subject>Health aspects</subject><subject>Lactobacillus</subject><subject>Microbiota (Symbiotic organisms)</subject><subject>Physiological aspects</subject><subject>Probiotics</subject><issn>2072-6643</issn><issn>2072-6643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptkMtOwzAQRS0EElXphi-wxDqtH4mdLEtVaKQiKijryvEjNXJsFCcIvqC_TVpYdMHMYkZXZ-6MBoBbjKaUFmjme5whhjOCL8CIIE4SxlJ6edZfg0mM7-gYHHFGR-Cw_PpwobW-ht1ew03otO-scDAYWK6F7EIlpHWuj3Cv3afurOzjrIQvCGUECq9geW-NVUes063tG-iCr_vmxGCeQRHhpg2Njccdm_gt96GyYfCJ8O2kva7Kp-UNuDLCRT35q2OwfVhuF6tk_fxYLubrpGY8TZSRFOW5rPJKcMVzSUjOMmoEyXVGtJKGS1VgRaWuUmQILQouJCUCK1IoYegY3P3a1sLpnfUmdK2Qw3FyN-cp5azAw5vGYPoPNaTSjZXBa2MH_WzgB4S3czY</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>De Oliveira, Fellipe Lopes</creator><creator>Salgaço, Mateus Kawata</creator><creator>de Oliveira, Marina Toscano</creator><creator>Mesa, Victoria</creator><creator>Sartoratto, Adilson</creator><creator>Peregrino, Antonio Medeiros</creator><creator>Ramos, Williams Santos</creator><creator>Sivieri, Katia</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20230301</creationdate><title>Exploring the Potential of ILactobacillus helveticus/I R0052 and IBifidobacterium longum/I R0175 as Promising Psychobiotics Using SHIME</title><author>De Oliveira, Fellipe Lopes ; Salgaço, Mateus Kawata ; de Oliveira, Marina Toscano ; Mesa, Victoria ; Sartoratto, Adilson ; Peregrino, Antonio Medeiros ; Ramos, Williams Santos ; Sivieri, Katia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g674-dfc3088cb8ba7d78c228653fa28e52edcf7cd91d3ceb40f23997ac32a1d29daf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anxiety</topic><topic>Bifidobacterium</topic><topic>Development and progression</topic><topic>Diet therapy</topic><topic>Gastrointestinal system</topic><topic>Health aspects</topic><topic>Lactobacillus</topic><topic>Microbiota (Symbiotic organisms)</topic><topic>Physiological aspects</topic><topic>Probiotics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>De Oliveira, Fellipe Lopes</creatorcontrib><creatorcontrib>Salgaço, Mateus Kawata</creatorcontrib><creatorcontrib>de Oliveira, Marina Toscano</creatorcontrib><creatorcontrib>Mesa, Victoria</creatorcontrib><creatorcontrib>Sartoratto, Adilson</creatorcontrib><creatorcontrib>Peregrino, Antonio Medeiros</creatorcontrib><creatorcontrib>Ramos, Williams Santos</creatorcontrib><creatorcontrib>Sivieri, Katia</creatorcontrib><jtitle>Nutrients</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>De Oliveira, Fellipe Lopes</au><au>Salgaço, Mateus Kawata</au><au>de Oliveira, Marina Toscano</au><au>Mesa, Victoria</au><au>Sartoratto, Adilson</au><au>Peregrino, Antonio Medeiros</au><au>Ramos, Williams Santos</au><au>Sivieri, Katia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring the Potential of ILactobacillus helveticus/I R0052 and IBifidobacterium longum/I R0175 as Promising Psychobiotics Using SHIME</atitle><jtitle>Nutrients</jtitle><date>2023-03-01</date><risdate>2023</risdate><volume>15</volume><issue>6</issue><issn>2072-6643</issn><eissn>2072-6643</eissn><abstract>Psychobiotics are probiotics that have the characteristics of modulating central nervous system (CNS) functions or reconciled actions by the gut–brain axis (GBA) through neural, humoral and metabolic pathways to improve gastrointestinal activity as well as anxiolytic and even antidepressant abilities. The aim of this work was to evaluate the effect of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 on the gut microbiota of mildly anxious adults using SHIME[sup.®]. The protocol included a one-week control period and two weeks of treatment with L. helveticus R0052 and B. longum R0175. Ammonia (NH4+), short chain fatty acids (SCFAs), gamma-aminobutyric acid (GABA), cytokines and microbiota composition were determined. Probiotic strains decreased significantly throughout the gastric phase. The highest survival rates were exhibited by L. helveticus R0052 (81.58%; 77.22%) after the gastric and intestinal phase when compared to B. longum (68.80%; 64.64%). At the genus level, a taxonomic assignment performed in the ascending colon in the SHIME[sup.®] model showed that probiotics (7 and 14 days) significantly (p &lt; 0.005) increased the abundance of Lactobacillus and Olsenella and significantly decreased Lachnospira and Escheria-Shigella. The probiotic treatment (7 and 14 days) decreased (p &lt; 0.001) NH[sub.4] [sup.+] production when compared to the control period. For SCFAs, we observed after probiotic treatment (14 days) an increase (p &lt; 0.001) in acetic acid production and total SCFAs when compared to the control period. Probiotic treatment increased (p &lt; 0.001) the secretion of anti-inflammatory (IL-6 and IL-10) and decreased (p &lt; 0.001) pro-inflammatory cytokines (TNF-alpha) when compared to the control period. The gut–brain axis plays an important role in the gut microbiota, producing SCFAs and GABA, stimulating the production of anti-anxiety homeostasis. The signature of the microbiota in anxiety disorders provides a promising direction for the prevention of mental illness and opens a new perspective for using the psychobiotic as a main actor of therapeutic targets.</abstract><pub>MDPI AG</pub><doi>10.3390/nu15061521</doi></addata></record>
fulltext fulltext
identifier ISSN: 2072-6643
ispartof Nutrients, 2023-03, Vol.15 (6)
issn 2072-6643
2072-6643
language eng
recordid cdi_gale_infotracmisc_A743769164
source Publicly Available Content (ProQuest); PubMed
subjects Anxiety
Bifidobacterium
Development and progression
Diet therapy
Gastrointestinal system
Health aspects
Lactobacillus
Microbiota (Symbiotic organisms)
Physiological aspects
Probiotics
title Exploring the Potential of ILactobacillus helveticus/I R0052 and IBifidobacterium longum/I R0175 as Promising Psychobiotics Using SHIME
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A35%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20the%20Potential%20of%20ILactobacillus%20helveticus/I%20R0052%20and%20IBifidobacterium%20longum/I%20R0175%20as%20Promising%20Psychobiotics%20Using%20SHIME&rft.jtitle=Nutrients&rft.au=De%20Oliveira,%20Fellipe%20Lopes&rft.date=2023-03-01&rft.volume=15&rft.issue=6&rft.issn=2072-6643&rft.eissn=2072-6643&rft_id=info:doi/10.3390/nu15061521&rft_dat=%3Cgale%3EA743769164%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g674-dfc3088cb8ba7d78c228653fa28e52edcf7cd91d3ceb40f23997ac32a1d29daf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A743769164&rfr_iscdi=true